AU2020218337A1 - Recombinant nucleic acids containing alphaherpesvirus promoter sequences - Google Patents

Recombinant nucleic acids containing alphaherpesvirus promoter sequences Download PDF

Info

Publication number
AU2020218337A1
AU2020218337A1 AU2020218337A AU2020218337A AU2020218337A1 AU 2020218337 A1 AU2020218337 A1 AU 2020218337A1 AU 2020218337 A AU2020218337 A AU 2020218337A AU 2020218337 A AU2020218337 A AU 2020218337A AU 2020218337 A1 AU2020218337 A1 AU 2020218337A1
Authority
AU
Australia
Prior art keywords
cell
seq
nucleic acid
promoter
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2020218337A
Other languages
English (en)
Inventor
Esteban ENGEL
Lynn ENQUIST
Carola MATURANA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Princeton University
Original Assignee
Princeton University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Princeton University filed Critical Princeton University
Publication of AU2020218337A1 publication Critical patent/AU2020218337A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16722—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
AU2020218337A 2019-02-05 2020-02-05 Recombinant nucleic acids containing alphaherpesvirus promoter sequences Abandoned AU2020218337A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962801524P 2019-02-05 2019-02-05
US62/801,524 2019-02-05
US201962950848P 2019-12-19 2019-12-19
US62/950,848 2019-12-19
PCT/US2020/016787 WO2020163475A1 (en) 2019-02-05 2020-02-05 Recombinant nucleic acids containing alphaherpesvirus promoter sequences

Publications (1)

Publication Number Publication Date
AU2020218337A1 true AU2020218337A1 (en) 2021-08-26

Family

ID=71947095

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020218337A Abandoned AU2020218337A1 (en) 2019-02-05 2020-02-05 Recombinant nucleic acids containing alphaherpesvirus promoter sequences

Country Status (11)

Country Link
US (1) US12551574B2 (enExample)
EP (1) EP3921431A4 (enExample)
JP (2) JP7658580B2 (enExample)
KR (1) KR20210125014A (enExample)
CN (1) CN113383082A (enExample)
AU (1) AU2020218337A1 (enExample)
BR (1) BR112021015281A2 (enExample)
CA (1) CA3127019A1 (enExample)
MX (1) MX2021009161A (enExample)
SG (1) SG11202108111WA (enExample)
WO (1) WO2020163475A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7658580B2 (ja) 2019-02-05 2025-04-08 ザ、トラスティーズ オブ プリンストン ユニバーシティ アルファヘルペスウイルスプロモーター配列を含む組換え核酸
US20250025575A1 (en) * 2021-11-23 2025-01-23 The Trustees Of Princeton University Compositions and Methods for Cell-Specific Expression of Target Genes
WO2026032009A1 (en) * 2024-08-06 2026-02-12 Chinese Institute For Brain Research, Beijing (Cibr) A microglia-specific regulatory element for aav-mediated transgene manipulation

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5352596A (en) * 1992-09-11 1994-10-04 The United States Of America As Represented By The Secretary Of Agriculture Pseudorabies virus deletion mutants involving the EPO and LLT genes
US7341847B2 (en) * 2003-04-02 2008-03-11 Agency For Science, Technology And Research Promoter construct for gene expression in neuronal cells
WO2005080581A2 (en) * 2004-02-17 2005-09-01 University Of Florida Research Foundation, Inc. Insulated herpesvirus-derived gene expression cassettes for sustained and regulatable gene expression
EP2058401A1 (en) 2007-10-05 2009-05-13 Genethon Widespread gene delivery to motor neurons using peripheral injection of AAV vectors
JP7090548B2 (ja) 2016-01-29 2022-06-24 ジリオン バイオテック ゲーエムベーハー Ａａｖ系条件的発現系
JP7658580B2 (ja) 2019-02-05 2025-04-08 ザ、トラスティーズ オブ プリンストン ユニバーシティ アルファヘルペスウイルスプロモーター配列を含む組換え核酸
US20250025575A1 (en) 2021-11-23 2025-01-23 The Trustees Of Princeton University Compositions and Methods for Cell-Specific Expression of Target Genes

Also Published As

Publication number Publication date
EP3921431A1 (en) 2021-12-15
CA3127019A1 (en) 2020-08-13
JP7658580B2 (ja) 2025-04-08
WO2020163475A1 (en) 2020-08-13
JP2025026584A (ja) 2025-02-21
JP2022518867A (ja) 2022-03-16
BR112021015281A2 (pt) 2021-10-05
EP3921431A4 (en) 2022-12-14
CN113383082A (zh) 2021-09-10
KR20210125014A (ko) 2021-10-15
MX2021009161A (es) 2021-09-10
US12551574B2 (en) 2026-02-17
SG11202108111WA (en) 2021-08-30
US20220378941A1 (en) 2022-12-01

Similar Documents

Publication Publication Date Title
CN109641939B (zh) 变体腺伴随病毒及使用方法
ES2941502T3 (es) Variantes de cápsides de virus adenoasociado y procedimientos de utilización de las mismas
US20210355503A1 (en) Compositions and methods for manufacturing gene therapy vectors
JP2024015408A (ja) 高活性制御エレメント
WO2022235702A1 (en) Recombinant aavs for delivery to central nervous system and brain vasculature
EP3561062A1 (en) Selective recovery
JP2025026584A (ja) アルファヘルペスウイルスプロモーター配列を含む組換え核酸
US20240139329A1 (en) Targets for Receptor-Mediated Control of Therapeutic Biodistribution and Efficacy
CN113710693B (zh) Dna结合结构域反式激活因子及其用途
Maturana et al. Small alphaherpesvirus latency-associated promoters drive efficient and long-term transgene expression in the CNS
CN112680443A (zh) 一种启动子pCalm1及其应用
US20230279405A1 (en) Dna-binding domain transactivators and uses thereof
US20250025575A1 (en) Compositions and Methods for Cell-Specific Expression of Target Genes
Galvan et al. MiniPromoters Ple384 (TH) and Ple388 (PITX3) for targeting midbrain dopaminergic neurons in mice and monkeys
TWI883636B (zh) 含有星狀細胞導向啟動子構築體之合成核酸及其使用方法
WO2025235689A2 (en) Peptides targeting alpl for blood-brain barrier crossing
HK40016209A (en) Selective recovery

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application